Sara Vesely to Rituximab
This is a "connection" page, showing publications Sara Vesely has written about Rituximab.
Connection Strength
0.657
-
Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial. Transfusion. 2017 10; 57(10):2532-2538.
Score: 0.141
-
Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2016 06 16; 127(24):3092-4.
Score: 0.129
-
Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion. 2012 Dec; 52(12):2525-32; quiz 2524.
Score: 0.098
-
Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher. 2006 Apr; 21(1):49-56.
Score: 0.065
-
Thrombotic thrombocytopenic purpura: from the bench to the bedside, but not yet to the community. Ann Intern Med. 2003 Jan 21; 138(2):152-3.
Score: 0.052
-
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020 10; 18(10):2496-2502.
Score: 0.044
-
Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020 10; 18(10):2503-2512.
Score: 0.044
-
The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood. 2015 Mar 05; 125(10):1526-31.
Score: 0.030
-
Management of primary immune thrombocytopenia, 2012: a survey of oklahoma hematologists-oncologists. Am J Med Sci. 2014 Mar; 347(3):190-4.
Score: 0.028
-
Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer. 2013 Oct; 60(10):1676-82.
Score: 0.027